Yu Three Gorges A into methionine proposed 3 billion acquisition of Ningxia Ziguang.

OA_show ('533');Yu Three Gorges A intends to purchase its 100% stake in Ningxia Ziguang from Chongqing Ziguang by issuing sharesThe consideration was initially set at RMB309,346.37 million, with an issue price of RMB 9.00 per share and 343,718,188 shares issuedThe transaction constitutes an associated transaction due to the direct holding of 45.21% of chongqing Ziguang, the company's controlling shareholder, The Medical GroupThe company's shares will continue to be suspendedPrior to ZiS, the total share capital of Yu Sanxia was433,592,220 sharesIn this transaction, Yu Three Gorges intends to issue 343,718,188 shares to Chongqing ZiguangUpon completion of the transaction, the Company's share capital will increase from 433,592,220 shares to 777,310,408 sharesBefore and after ZiS's offering, the company's equity structure changed as follows (number: shares; percentage: %): ZiSProject ZiSZiSbefore this transaction ZiSthe number of ZiSholdings zis the number of ZiS holdings ZiS 175,808,982 ZiS 982ZiS 22.62ZiS Chongqing Ziguang ZiS -ZiS -ZiS 343,718,188ZiS 44.22ZiS other shareholders ZiS 257,783,238ZiS 59.45ZiS 257,783,238ZiZ 33.16ZiS Total ZiS 433,592,220ZiS 100.00ZiS 777,310,408ZiS 100.00ZiS Ningxia Ziguang's main business is feed-grade DL-methine research and development, production and sales According to unaudited financial statements, in 2014, 2015 and January-July 2016, Ningxia Ziguang achieved revenue of RMB24 million, RMB1,137 million and RMB660 million, respectively, and realized net profit of RMB016 million, RMB254 million and RMB153 million ZiS Ningxia Ziguang is a wholly owned subsidiary of Chongqing Ziguang Chemical Medical Group is the controlling shareholder of Chongqing Ziguang, Chongqing SASAC holds 100% of the shares of Chemical Medical Group, so the actual controller of Ningxia Ziguang is the Chongqing SASAC ZiS ZiS ZiS Ningxia Ziguang methine production capacity, production, sales volume and sales revenue are shown in the following table (amount: 10,000 yuan; quantity: tons) ZiS project ZiS January-July 2016 ZiS 2015 ZiS 2014 NoteS ZiZiZiZi 50,0 00.00.000.000.000.000 000.000.000.000.000.00 ZiS Production ZiS 30,190.36 ZiS 39,093.76 ZiS 1,049.76 ZiS Sales ZiS 25,794.64 ZiS 36,828.95 ZiS 68.71 ZiS Sales 61999.05 108206.16 ZiS 2292.96 ZiS as of the signing date of this plan, Ningxia Ziguang Phase I 50,000 tons / year feed-grade DL-methine and industrial supporting projects have been completed and officially produced and run, the second phase of 50,000 tons / year feed-grade DL-methine and industrial supportprojects have been completed, in the trial production stage At present, Ningxia Ziguang's feed-grade DL-methine production capacity of 100,000 tons/year ZiS ZiS OA_show ('533'); Yu Sanxia A intends to purchase 100% of its stake in Ningxia Ziguang from Chongqing Ziguang by issuing shares The consideration was initially set at RMB309,346.37 million, with an issue price of RMB 9.00 per share and 343,718,188 shares issued The transaction constitutes an associated transaction due to the direct holding of 45.21% of chongqing Ziguang, the company's controlling shareholder, The Medical Group The company's shares will continue to be suspended Prior to ZiS, the total share capital of Yu Sanxia was 433,592,220 shares In this transaction, Yu Three Gorges intends to issue 343,718,188 shares to Chongqing Ziguang Upon completion of the transaction, the Company's share capital will increase from 433,592,220 shares to 777,310,408 shares Before and after ZiS's offering, the company's equity structure changed as follows (number: shares; percentage: %): ZiS Project ZiS ZiS before this transaction Zi S the number of ZiS holdings zi s the number of ZiS holdings ZiS 175,808,982 ZiS 982ZiS 22.62ZiS Chongqing Ziguang ZiS -ZiS -ZiS 343,718,188ZiS 44.22ZiS other shareholders ZiS 257,783,238ZiS 59.45ZiS 257,783,238ZiZ 33.16ZiS Total ZiS 433,592,220ZiS 100.00ZiS 777,310,408ZiS 100.00ZiS Ningxia Ziguang's main business is feed-grade DL-methine research and development, production and sales According to unaudited financial statements, in 2014, 2015 and January-July 2016, Ningxia Ziguang achieved revenue of RMB24 million, RMB1,137 million and RMB660 million, respectively, and realized net profit of RMB016 million, RMB254 million and RMB153 million ZiS Ningxia Ziguang is a wholly owned subsidiary of Chongqing Ziguang Chemical Medical Group is the controlling shareholder of Chongqing Ziguang, Chongqing SASAC holds 100% of the shares of Chemical Medical Group, so the actual controller of Ningxia Ziguang is the Chongqing SASAC ZiS ZiS ZiS Ningxia Ziguang methine production capacity, production, sales volume and sales revenue are shown in the following table (amount: 10,000 yuan; quantity: tons) ZiS project ZiS January-July 2016 ZiS 2015 ZiS 2014 NoteS ZiZiZiZi 50,0 00.00.000.000.000.000 000.000.000.000.000.00 ZiS Production ZiS 30,190.36 ZiS 39,093.76 ZiS 1,049.76 ZiS Sales ZiS 25,794.64 ZiS 36,828.95 ZiS 68.71 ZiS Sales 61999.05 108206.16 ZiS 2292.96 ZiS as of the signing date of this plan, Ningxia Ziguang Phase I 50,000 tons / year feed-grade DL-methine and industrial supporting projects have been completed and officially produced and run, the second phase of 50,000 tons / year feed-grade DL-methine and industrial supportprojects have been completed, in the trial production stage At present, Ningxia Ziguang's feed-grade DL-methine production capacity of 100,000 tons/year ZiS ZiS .